#cd47

Live, measured metrics for the hashtag #cd47 from the open social web. Every number carries a named source and the time it was fetched. Nothing is estimated.

hashtag.org network · sponsored

Own #cd47

This #name is available to claim. It becomes your portal on the open agent web: this very page, a keyword you rank for by an open public stake, and a verifiable identity for AI agents. Nobody else sells a page like this for every #name.

$2,449.80/ year · 4-character #name
Claim #cd47 — $2,449.80/yr→Buy on hashtag.space (web3)
card via hashtag.org · tokens via hashtag.space
0
Uses / 7 days
Mastodon
0
Accounts / 7 days
Mastodon
4
Recent posts
Mastodon
~0/hr
Recent pace
Mastodon · last 4
0
Avg reactions / post
Mastodon · last 4

Day-by-day usage

measured · fosstodon.org (Mastodon public tags API) · fetched 2026-07-28 04:02 UTC
0
07-22
0
07-23
0
07-24
0
07-25
0
07-26
0
07-27
0
07-28

0 uses by 0 unique accounts across the window. Real per-day counts, not estimates. Newest bar is today so far.

Related hashtags

measured · fosstodon.org (Mastodon public search API) · fetched 2026-07-28 04:02 UTC
#a9260cd47a0
0 uses · 0 accounts / 7d
#47cd4b
0 uses · 0 accounts / 7d
#47A8CD
0 uses · 0 accounts / 7d
#47CD0B
0 uses · 0 accounts / 7d
#CD3C47
0 uses · 0 accounts / 7d
#CD47D7
0 uses · 0 accounts / 7d
#7CD47C
0 uses · 0 accounts / 7d
#C47CD7
0 uses · 0 accounts / 7d
#uuid_057b3ea1c47f41c58955d8bd0ea002cd
0 uses · 0 accounts / 7d

Live pulse

measured · fosstodon.org (Mastodon tag timeline) · fetched 2026-07-28 04:02 UTC

Everything below is measured over the latest 4 public posts (spanning ~32159 hours).

Posting hours (UTC)

00:0012:0023:00

Languages: English (3)

Avg boosts / post: 0.3

Top of the latest posts

  • AI時代新藥設計：漢康生技如何用「蛋白質工程」，賭一個45億美元授權？林昆輝（Quinn Lin） 2026-07-12 07:58:00 CST漢康的CD47新藥HCB101，運用AI輔助蛋白質工程，突破前代藥物安全性與療效的兩難，能高選擇性攻擊腫瘤而不傷紅血球，目標在完成概念驗證後進行國際授權。 https://www.thenewslens.com/article/269119 #蛋白質工程 #免疫系統 #AI輔助蛋白質工程 #腫瘤細胞 #FDA #巨噬細胞 #商業 #

    The News Lens@[email protected]♥ 0↻ 02026-07-12 00:29 UTCView post →

  • Magrolimab is an anti-CD47 'Gilead Sciences, Inc. today announced it has discontinued the Phase 3 ENHANCE-3 study of magrolimab in AML and that the (FDA) placed all magrolimab studies in myelodysplastic syndromes and AML, including related

    Thiago Carvalho@[email protected]♥ 0↻ 02024-02-08 07:40 UTCView post →

  • " Instead, #Hepatoblastoma #tumors contain a large suppressive #myeloid compartment which poses opportunities for targeting. Specifically, therapeutic antibodies targeting the #tumor antigen #GPC3 to induce ADCP by #macrophages, in combinat

    Arjan Boltjes@[email protected]♥ 0↻ 02023-07-14 14:21 UTCView post →

Every number above is measured from a named public API at the shown fetch time. Nothing is estimated or extrapolated. Platforms that lock their data behind paid APIs are not shown. Agents: the same numbers, as JSON, at /api/hashtags/cd47